marijuana stocks

Affinor Growers, Inc. (RSSFF)

–Other OTC

0.13 Up 0.00(3.47%) 1:36PM EST
Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Nov 30, 2014 Aug 31, 2014 May 31, 2014 Feb 28, 2014
Total Revenue 41   43   –   –  
Cost of Revenue – – – –
Gross Profit 41   43   –   –  
Operating Expenses
Research Development – – – –
Selling General and Administrative 1,145 1,342 7,187 95
Non Recurring – – – –
Others 8 5 – –
Total Operating Expenses – – – –
Operating Income or Loss (1,113) (1,304) (7,298) (95)
Income from Continuing Operations
Total Other Income/Expenses Net (12) 21 9 (9)
Earnings Before Interest And Taxes (1,125) (1,283) (7,290) (104)
Interest Expense – – 0 (1)
Income Before Tax (1,125) (1,283) (7,290) (104)
Income Tax Expense – – (6) 2
Minority Interest – – – –
Net Income From Continuing Ops (1,125) (1,283) (7,283) (105)
Non-recurring Events
Discontinued Operations – – – –
Extraordinary Items – – – –
Effect Of Accounting Changes – – – –
Other Items – – – –
Net Income (1,125) (1,283) (7,283) (105)
Preferred Stock And Other Adjustments – – – –
Net Income Applicable To Common Shares (1,125) (1,283) (7,283) (105)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

AbbVie Inc. (ABBV) and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets

AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage…

$MJNA Receives Positive PK Data Results

Medical Marijuna, Inc. Investment AXIM(R) Biotech Receives Positive PK Data Results for…

 AgraFlora Organics International Inc. (AGRA) (AGFAF) Introduces Initial Edibles SKUs for Production

AgraFlora Organics Introduces Initial Edibles SKUs for Production at 51,500 Sq. Ft.…

Cara Therapeutics, Inc. (CARA) Announces Successful End-of-Phase 2 Meeting with FDA

Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845…